MedTrace Logo

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

NCT04712266 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-01-15

No results posted yet for this study

Summary

This is a single center, double-blind, randomized trial in subjects with type 1 diabetes mellitus applying an adaptive design approach.

Conditions

  • Type 1 Diabetes Mellitus With Hypoglycemia

Interventions

DRUG

Glucagon

calculated IV insulin:Glucagon molar ratio

DRUG

Insulin

calculated IV Insulin dose infused at a constant rate

Sponsors & Collaborators

  • T1D Exchange, United States

    collaborator OTHER

  • Abvance Therapeutics

    lead INDUSTRY

Principal Investigators

  • Bruce Bode, MD · Atlanta Diabetes Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-12-15
Completion
2021-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04712266 on ClinicalTrials.gov